 | • レポートコード：D0SP201106 • 出版社/出版日：Transparency Market Research / 2020年10月30日 • レポート形態：英文、PDF、231ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本市場調査レポートでは、抗ウイルス併用療法の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、キーインサイト、配合剤別（NRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他）分析、種類別（ブランド、ジェネリック）分析、疾患別（HIV、肝炎、その他）分析、投与経路別（経口、静脈内）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場動向 ・キーインサイト ・抗ウイルス併用療法の世界市場規模：配合剤別（NRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他） ・抗ウイルス併用療法の世界市場規模：種類別（ブランド、ジェネリック） ・抗ウイルス併用療法の世界市場規模：疾患別（HIV、肝炎、その他） ・抗ウイルス併用療法の世界市場規模：投与経路別（経口、静脈内） ・抗ウイルス併用療法の世界市場規模：流通チャネル別（病院薬局、小売薬局、その他） ・抗ウイルス併用療法の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Antiviral Combination Therapies Market – Scope of the Report
TMR’s report on the global antiviral combination therapies market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global antiviral combination therapies market from 2018 to 2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global antiviral combination therapies market for the forecast period.
The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with market leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global antiviral combination therapies market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the global antiviral combination therapies market.
The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competition dynamics in the global antiviral combination therapies market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global antiviral combination therapies market. The next section of the report highlights the USPs, which include major selling antiviral combination drugs, patent information of combination therapies pipeline analysis, key industry events, disease epidemiology, and COVID-19 pandemic impact on industry (value chain and short/mid/long term impact) in the global antiviral combination therapies market.
The report delves into the competition landscape of the global antiviral combination therapies market. Key players operating in the global antiviral combination therapies market have been identified and each one of these has been profiled for its distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global antiviral combination therapies market report.
Key Questions Answered in Antiviral Combination Therapies Market Report
What will be the sales revenue generated by antiviral combination therapies across all regions during the forecast period?
What are the key trends in the global antiviral combination therapies market?
What are major drivers, restraints, and opportunities in the global antiviral combination therapies market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which indication segment will generate the maximum revenue by 2030 and which product segment will expand at the fastest CAGR during the forecast period?
Antiviral Combination Therapies Market – Research Objectives and Research Approach
The comprehensive report on the global antiviral combination therapies market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global antiviral combination therapies market. It is followed by market introduction, market dynamics, and an overview of the global antiviral combination therapies market, which includes TMR’s analysis of market drivers, restraints, and trends affecting the market. Furthermore, the Y-o-Y growth analysis with elaborate insights has been provided to understand the Y-o-Y growth trends of the global market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
Revenue generated by key players in the global antiviral combination therapies market has been mapped to ascertain the size of the market in terms of value. The forecast presented here assesses the total revenue generated in the global antiviral combination therapies market. In order to provide an accurate forecast, we initiated by sizing up the current antiviral combination therapies market with the help of the parent market.
The report analyzes the global antiviral combination therapies market in terms of drug combination, type, indication, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length and the market share of each of these by the end of 2030 has been provided. These valuable insights would help stakeholders in making informed business decisions for investments in the global antiviral combination therapies market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antiviral Combination Therapies Market
4. Market Overview
4.1. Definition
4.2. Market Indicators
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018–2030
4.5. Global Antiviral Combination Therapies Market Outlook
5. Key Insights
5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.2. Major Selling Antiviral Combination Drugs
5.3. Patent Information of Combination Therapies
5.4. Pipeline Analysis
5.5. Key Industry Events
5.6. Disease Epidemiology
6. Global Antiviral Combination Therapies Market Analysis and Forecast, by Drug Combination
6.1. Introduction
6.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination
6.3. Global Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
6.3.1. NRTI/NNRTI
6.3.2. Integrase Inhibitor/NRTI
6.3.3. NRTI
6.3.4. NRTI/Protease Inhibitor
6.3.5. Others
6.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination
7. Global Antiviral Combination Therapies Market Analysis and Forecast, by Type
7.1. Introduction
7.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Type
7.3. Global Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
7.3.1. Branded
7.3.2. Generic
7.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type
8. Global Antiviral Combination Therapies Market Analysis and Forecast, by Indication
8.1. Introduction
8.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Indication
8.3. Global Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
8.3.1. HIV
8.3.2. Hepatitis
8.3.3. Others
8.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication
9. Global Antiviral Combination Therapies Market Analysis and Forecast, by Route of Administration
9.1. Introduction
9.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration
9.3. Global Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
9.3.1. Oral
9.3.2. Intravenous
9.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration
10. Global Antiviral Combination Therapies Market Analysis and Forecast, by Distribution Channel
10.1. Introduction
10.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel
10.3. Global Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Others
10.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel
11. Global Antiviral Combination Therapies Market Analysis and Forecast, by Region
11.1. Regional Outlook
11.2. Introduction
11.3. Global Antiviral Combination Therapies Market Value Forecast, by Region
11.3.1. North America
11.3.2. Europe
11.3.3. Asia Pacific
11.3.4. Latin America
11.3.5. Middle East & Africa
11.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region
12. North America Antiviral Combination Therapies Market Analysis and Forecast
12.1. Key Findings
12.2. North America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
12.2.1. NRTI/NNRTI
12.2.2. Integrase Inhibitor/NRTI
12.2.3. NRTI
12.2.4. NRTI/Protease Inhibitor
12.2.5. Others
12.3. North America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
12.3.1. Branded
12.3.2. Generic
12.4. North America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
12.4.1. HIV
12.4.2. Hepatitis
12.4.3. Others
12.5. North America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
12.5.1. Oral
12.5.2. Intravenous
12.6. North America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Others
12.7. North America Antiviral Combination Therapies Market Value Forecast, by Country, 2018–2030
12.7.1. U.S.
12.7.2. Canada
12.8. North America Antiviral Combination Therapies Attractiveness Analysis
12.8.1. By Drug Combination
12.8.2. By Type
12.8.3. By Indication
12.8.4. By Route of Administration
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Antiviral Combination Therapies Market Analysis and Forecast
13.1. Key Findings
13.2. Europe Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
13.2.1. NRTI/NNRTI
13.2.2. Integrase Inhibitor/NRTI
13.2.3. NRTI
13.2.4. NRTI/Protease Inhibitor
13.2.5. Others
13.3. Europe Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
13.3.1. Branded
13.3.2. Generic
13.4. Europe Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
13.4.1. HIV
13.4.2. Hepatitis
13.4.3. Others
13.5. Europe Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
13.5.1. Oral
13.5.2. Intravenous
13.6. Europe Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Others
13.7. Europe Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
13.7.1. U.K.
13.7.2. Germany
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Europe Antiviral Combination Therapies Market Attractiveness Analysis
13.8.1. By Drug Combination
13.8.2. By Type
13.8.3. By Indication
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Antiviral Combination Therapies Market Analysis and Forecast
14.1. Key Findings
14.2. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
14.2.1. NRTI/NNRTI
14.2.2. Integrase Inhibitor/NRTI
14.2.3. NRTI
14.2.4. NRTI/Protease Inhibitor
14.2.5. Others
14.3. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
14.3.1. Branded
14.3.2. Generic
14.4. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
14.4.1. HIV
14.4.2. Hepatitis
14.4.3. Others
14.5. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
14.5.1. Oral
14.5.2. Intravenous
14.6. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Others
14.7. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
14.7.1. China
14.7.2. India
14.7.3. Japan
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis
14.8.1. By Drug Combination
14.8.2. By Type
14.8.3. By Indication
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Antiviral Combination Therapies Market Analysis and Forecast
15.1. Key Findings
15.2. Latin America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
15.2.1. NRTI/NNRTI
15.2.2. Integrase Inhibitor/NRTI
15.2.3. NRTI
15.2.4. NRTI/Protease Inhibitor
15.2.5. Others
15.3. Latin America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
15.3.1. Branded
15.3.2. Generic
15.4. Latin America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
15.4.1. HIV
15.4.2. Hepatitis
15.4.3. Others
15.5. Latin America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
15.5.1. Oral
15.5.2. Intravenous
15.6. Latin America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Others
15.7. Latin America Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Latin America Antiviral Combination Therapies Market Attractiveness Analysis
15.8.1. By Drug Combination
15.8.2. By Type
15.8.3. By Indication
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Antiviral Combination Therapies Market Analysis and Forecast
16.1. Key Findings
16.2. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
16.2.1. NRTI/NNRTI
16.2.2. Integrase Inhibitor/NRTI
16.2.3. NRTI
16.2.4. NRTI/Protease Inhibitor
16.2.5. Others
16.3. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
16.3.1. Branded
16.3.2. Generic
16.4. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
16.4.1. HIV
16.4.2. Hepatitis
16.4.3. Others
16.5. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
16.5.1. Oral
16.5.2. Intravenous
16.6. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Others
16.7. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis
16.8.1. By Drug Combination
16.8.2. By Type
16.8.3. By Indication
16.8.4. By Route of Administration
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis, by Company, 2019
17.3. Company Profiles
17.3.1. Celltrion, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Strategic Overview
17.3.1.5. SWOT Analysis
17.3.2. GlaxoSmithKline plc
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Strategic Overview
17.3.2.5. SWOT Analysis
17.3.3. Gilead Sciences, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Strategic Overview
17.3.3.5. SWOT Analysis
17.3.4. AbbVie, Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Strategic Overview
17.3.4.5. SWOT Analysis
17.3.5. Bristol-Myers Squibb Company
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Strategic Overview
17.3.5.5. SWOT Analysis
17.3.6. Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Strategic Overview
17.3.6.5. SWOT Analysis
17.3.7. Cipla, Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Strategic Overview
17.3.7.5. SWOT Analysis
17.3.8. Mylan N.V.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Strategic Overview
17.3.8.5. SWOT Analysis
17.3.9. Merck & Co., Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Strategic Overview
17.3.9.5. SWOT Analysis
17.3.10. F. Hoffmann-La Roche Ltd.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Strategic Overview
17.3.10.5. SWOT Analysis
List of TablesTable 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 02: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 03: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 04: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 05: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 09: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 10: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 11: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 12: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 15: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 16: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 17: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 18: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 19: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 21: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 22: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 23: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 24: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 27: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 28: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 29: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 30: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 31: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 33: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 34: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 35: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 36: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030